SNP-ACTH Gel for Kidney Disease
Trial Summary
Will I have to stop taking my current medications?
The trial protocol suggests that if you have relapsed after certain immunosuppressive therapies, you need to wait a specific period before joining: more than 3 months for glucocorticoids, calcineurin inhibitors, or mycophenolate mofetil; more than 6 months for chlorambucil or cyclophosphamide; and more than 12 months for rituximab. It doesn't specify about other medications, so it's best to discuss with the trial team.
What data supports the effectiveness of the drug Rituximab for kidney disease?
Rituximab has shown effectiveness in reducing proteinuria (excess protein in urine) in patients with primary membranous nephropathy, a type of kidney disease, as demonstrated in well-powered randomized controlled trials. It is considered a valid alternative to other treatments like glucocorticoid-cyclophosphamide, although the optimal dosing and regimen are still being studied.12345
What safety data exists for Rituximab and related treatments in humans?
Rituximab, used for various conditions, is generally considered safe but can have rare serious side effects like infections, low blood cell counts, and reactivation of hepatitis B. Some patients may experience low potassium levels or late-onset side effects like neutropenia (low white blood cell count) and hypogammaglobulinemia (low antibody levels), which increase infection risk.36789
What makes the SNP-ACTH Gel treatment for kidney disease unique compared to other treatments?
The SNP-ACTH Gel treatment is unique because it combines Rituximab, a medication often used for autoimmune diseases and certain cancers, with a gel form of ACTH (adrenocorticotropic hormone), which may offer a novel approach to managing kidney disease by potentially reducing inflammation and modulating the immune system in a targeted manner.1011121314
What is the purpose of this trial?
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary membranous nephropathy (PMN) at month 24.
Eligibility Criteria
This trial is for patients with primary membranous nephropathy, a kidney disease. They should have a life expectancy over 24 months, confirmed diagnosis via biopsy or positive anti PLA2R antibody test if they have Nephrotic Syndrome, and be at high risk of worsening kidney function. Participants must not have had certain treatments recently and cannot have diabetes or sensitivity to porcine proteins.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase 3a Treatment
Dose finding phase with SNP-ACTH Gel treatment at two different dose levels for 12 months
Phase 3b Treatment
Comparison of SNP-ACTH Gel at optimal dose versus Rituximab over 12 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Rituximab
- SNP-ACTH (1-39) Gel
Rituximab is already approved in United States, European Union, Canada for the following indications:
- Non-Hodgkin's lymphoma
- Chronic lymphocytic leukemia
- Rheumatoid arthritis
- Granulomatosis with polyangiitis
- Microscopic polyangiitis
- Non-Hodgkin's lymphoma
- Chronic lymphocytic leukemia
- Rheumatoid arthritis
- Granulomatosis with polyangiitis
- Microscopic polyangiitis
- Non-Hodgkin's lymphoma
- Chronic lymphocytic leukemia
- Rheumatoid arthritis
- Granulomatosis with polyangiitis
- Microscopic polyangiitis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cerium Pharmaceuticals, Inc.
Lead Sponsor